Clinrova's Clinical Operations Lead manages every phase of your trial's site lifecycle — not as a monitor handed a running study, but as the same senior professional who evaluated the site before it was selected.
Our COL model ensures that the person who selects your sites is the same person managing them through close-out. There are no handoffs, no knowledge gaps, and no moment where accountability is unclear. Every phase of your trial is owned — not just monitored.
Clinrova is built for small-to-mid-size biotech running rare disease Phase 2 programs. Specifically: sponsors who have run a study with a large CRO, experienced the monitoring quality and cost predictability problems that come with it, and are ready for a different approach.
We also work with mid-size pharma sponsors who want the accountability of a boutique firm without sacrificing platform capability.
We are not the right fit for every study. If your program is outside rare disease Phase 2, contact us and we will tell you honestly whether we can serve it well.
Our primary focus is rare disease Phase 2. This is not a limitation — it is a deliberate choice that makes us better at it. Concentrated therapeutic area expertise, COL relationships with the investigator networks that matter most in rare disease, and an AI platform trained on the protocols and site behaviors specific to this space produce better outcomes than a generalist approach.
Phase I, Phase III, and medical device studies are evaluated on a case-by-case basis. Contact us to discuss fit.
We don't believe in drawn-out sales cycles or generic proposals. Our engagement process is fast, transparent, and built around your specific protocol — not a template.
We'll review it, tell you whether it's a fit, and provide a specific fixed-fee proposal with a named COL before you sign anything.